Acumen to discuss Quantum Alpha-Oriented antibodies and Alzheimer's research
Acumen Pharmaceuticals released an investor presentation detailing the MOA of sabirnetug (ACU193) for Alzheimer's disease and it expects cash to support operations into early 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed